NICE

News

NICE firms up NHS use of Vimizim for Morquio A syndrome

In 2015, NICE said that BioMarin's Vimizim could be used to treat patients with the ultra-rare disease Morquio A syndrome, while real-world data was collected on its efficacy.

News

NICE says no to Keytruda in triple-negative breast cancer

There isn't enough evidence to support the use of Merck & Co/MSD's Keytruda in combination with chemotherapy as a first-line treatment for advanced triple negative breast cancer, accord

Market Access

Time to ask companies why they don’t submit to NICE?

Companies can choose whether or not to submit to NICE to have their products appraised.

News

GSK’s ZEJULA gets green light for NHS use

The UK’s National Institute for Health and Care Excellence (NICE) has recommended GlaxoSmithKline’s (GSK) ZEJULA (niraparib) for some forms of ovarian, fallopian tube, and peritoneal cancer

Market Access

How do UK market access prospects look in 2022?

Leela Barham and Neil Grubert look back at what was expected for market access in 2021 a

News

Novo Nordisk gets NICE okay for obesity drug Wegovy

Novo Nordisk's new obesity therapy Wegovy has been recommended for routine NHS use by UK cost-effectiveness watchdog NICE, but in a narrower group of patients than is covered by its MHRA-ap